RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 41 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 41

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  2. Study siteAffiliated Hospital of Guangdong Medical University广东医科大学附属医院ZhanjiangHospital page
  3. Study siteAffiliated Hospital of Hebei University河北大学附属医院ShijiazhuangHospital page
  4. Study siteAffiliated Hospital of Inner Mongolia Medical University内蒙古医科大学附属医院HohhotHospital page
  5. Study siteAnhui Chest Hospital安徽省胸科医院HefeiHospital page
  6. Study siteBeijing Chest Hospital首都医科大学附属北京胸科医院BeijingHospital page
  7. Study siteCentral Hospital Affiliated to Shandong First Medical University山东第一医科大学附属中心医院(济南市中心医院)JinanHospital page
  8. Study siteFirst Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院ChongqingHospital page
  9. Study siteFirst Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院GuangzhouHospital page
  10. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  11. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  12. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  13. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  14. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  15. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  16. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  17. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  18. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  19. Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
  20. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  21. Study siteJilin Cancer Hospital吉林省肿瘤医院ChangchunHospital page
  22. Study siteLinYi Cancer HospitalLinyiHospital page
  23. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
  24. Study siteNantong Tumor Hospital南通市肿瘤医院NantongHospital page
  25. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  26. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  27. Study siteSecond Affiliated Hospital of Nanchang University南昌大学第二附属医院NanchangHospital page
  28. Study siteSecond Hospital of Dalian Medical University大连医科大学附属第二医院DalianHospital page
  29. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  30. Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page
  31. Study siteShantou University Medical College hospitals汕头大学医学院附属医院ShantouHospital page
  32. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  33. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  34. Study siteTaizhou Hospital, Wenzhou Medical University温州医科大学附属台州医院TaizhouHospital page
  35. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  36. Study siteTianjin Medical University General Hospital天津医科大学总医院TianjinHospital page
  37. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  38. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  39. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  40. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
  41. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04928846, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. A histologically or cytologically documented non-squamous cell NSCLC that is locally advanced or metastatic.

    Inclusion criterion 5

  3. Have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting.

    Inclusion criterion 10

    Have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC

    Inclusion criterion 11

    Unresolved nor adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.

    Exclusion criterion 12

  4. An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.

    Inclusion criterion 9

  5. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Inclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04928846, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Projected life expectancy of at least 12 weeks.
  • Participants must have c-Met overexpressing non-small cell lung cancer (NSCLC) as assessed by an AbbVie designated immunohistochemistry (IHC) laboratory using the VENTANA MET (SP44) RxDx assay.
  • Archival or fresh tumor material must be submitted for assessment of c-Met protein expression levels during the Pre-Screening period. Tumor material from the primary tumor site and/or metastatic sites are allowed.
  • If a participant was prescreened for Study M14-239 but did not enroll, tumor material previously submitted for Study M14-239 may be used for Study M18-868 Pre-Screening upon confirmation from AbbVie that sufficient evaluable tumor material is available (Except China).
  • A histologically or cytologically documented non-squamous cell NSCLC that is locally advanced or metastatic.
  • A known epidermal growth factor receptor (EGFR) activating mutation status.

-- Participants with EGFR activating mutations are not eligible

  • Actionable alterations in genes other than EGFR are eligible.
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  • An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
  • Have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting.
  • Have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC
  • Participants WITHOUT an actionable gene alteration: must have progressed on (or be considered ineligible for) platinum-based chemotherapy and immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy).
  • Participants WITH an actionable gene alteration for which immune checkpoint inhibitor therapy is not standard of care (e.g., anaplastic lymphoma kinase [ALK] translocation): must have progressed on (or be considered ineligible for) anti-cancer therapy targeting driver gene alterations and platinum-based chemotherapy.
  • Participants with gene alterations for which immune checkpoint inhibitor is standard of care must have also progressed on (or be considered ineligible for) immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy).
  • Must be considered appropriate for docetaxel therapy based on the assessment of the treating physician.
  • Participants with metastases to the central nervous system (CNS) are eligible only after adequate treatment (such as surgery, radiotherapy, or drug therapy) is provided and:
  • They are asymptomatic and off or on a stable or reducing dose of systemic steroids (on no more than 10 mg per day [QD] prednisone or equivalent) and/or anticonvulsants for at least 2 weeks prior to randomization.

Exclusion Criteria:

  • Evidence of new, untreated CNS metastases or progressing CNS metastases after treatment.
  • Evidence of leptomeningeal disease.
  • Participants with adenosquamous or neuroendocrine histology, nor sarcomatoid features.
  • Epidermal growth factor receptor (EGFR) activating mutations.
  • Participants who have received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E..
  • Participants who have received prior docetaxel therapy.
  • A history of other malignancies except:
  • Malignancy treated with curative intent and with no known active disease present for >=2 years before the first dose of study drug and felt to be at low risk for recurrence by investigator. Additionally, participants must not be receiving any ongoing anti-cancer therapy, including maintenance therapy, prior to randomization..
  • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
  • Adequately treated carcinoma in situ without current evidence of disease.
  • A history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, evidence of active pneumonitis on screening chest computed tomography (CT) scan or prior pneumonectomy. A history of prior radiation pneumonitis in the radiation field (fibrosis) is not permitted.
  • Unresolved nor adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.
  • Major surgery within 21 days prior to randomization.
  • Clinically significant condition(s) as listed in the protocol.

Quoted from ClinicalTrials.gov, NCT04928846, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04928846, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04928846